In-Vitro Diagnostics (IVD) Quality Control Market Trends, Size, Share, Growth, Analysis And Forecast 2019-2026
IVD quality controls are tests
used to authenticate the consistency of IVD testing system to confirm precision
of test findings and assess the influence of factors such as environmental
conditions and operator’s performance on test results. Key recent developments:
in June 2019, Illumina, Inc. announced the launch of VeriSeq NIPT Solution v2,
a CE-IVD; next-generation sequencing (NGS)-based approach to noninvasive
prenatal testing (NIPT), delivers the most comprehensive view of the fetal
genome compared to other CE-IVD NIPT products.
Factors including increasing
prevalence of chronic diseases, launch of new clinical laboratories, stringent
mandates, as well as rising need of early diagnostics by patients drive the
growth of In-Vitro Diagnostics (IVD) Quality Control market. Increasing
incidence of public-private laboratories which are undergoing laboratory
accreditation procedure even boosts up the growth of this particular market.
For instance: In August 2018, Abbott Laboratories introduced Alinity, its
state-of-the-art, harmonized family of systems for clinical diagnostics, to the
US market indicating high demand for the systems’ advanced capabilities and
potential to provide savings and increased efficiencies for labs, clinicians,
and hospitals.
To identify the key trends in the industry, click on the
link below: https://www.reportsanddata.com/report-detail/in-vitro-diagnostics-ivd-quality-control-market
Further key findings from
the report suggest:
- The American Clinical Laboratory Association (ACLA)
states that more than 7.5 billion lab tests are performed in U.S. annually
and 80% of clinical decisions are taken after lab testing
- In December 2018, BioMérieux announced its culture
bottles BACT/ALERT® BPA and BPN have received 510(k) clearance from the
U.S. Food and Drug Administration (FDA) for quality control testing of
leukocyte-reduced apheresis platelet (LRAP) units with the BACT/ALERT®
VIRTUO® fully automated blood culture system
- In-Vitro Diagnostics (IVD) Quality Control Market is
fastest growing at a CAGR of 3% in Asia Pacific owing to rising incidence
of IVD tests in developing countries such as India and China due to
upsurge in number of clinical laboratories, global awareness among
patients
- FDA is encouraging convergence of regulatory systems
for medical devices, which is anticipated to boost trade, while protecting
public health through regulatory means
- Data Management Solutions segment is accounted to be
the second-leading segment which is valued at USD 155.6 million because it
gives access to LIS and easy for managing test results of patients and
even popular due to dependable laboratory outcomes
- Europe is the second largest region with a CAGR of
4.0% due to acceptance of point of care diagnostics across Europe
especially in regions in UK, Denmark, Poland and Slovenia
- Home Care segment is the fastest growing at a CAGR of
5.3% because they are providing PoC instruments which give ease of
convenience for the patient who requires everyday testing and further
reduces hospital visits
- Immunochemistry segment has dominated the market in
2018 with a market share over 30% and is expected to continue the same
during the forecasted period due to the demand for high sensitivity test
and even rise in communicable and chronic diseases
- North America is expected to account for the 44% of
the global In-Vitro Diagnostics (IVD) Quality Control Market million owing
to presence of many diagnostic laboratories and even production of
technologically advanced multianalyte controls
- Some of the key players are Agilent Diagnostics,
Abbott Diagnostics, Becton, Dickson and Company, Bio-Rad Laboratories,
Inc., and ThermoFisher Scientific
- The Japan was the major shareholder in the
Asia-Pacific market in 2015 with around half of market share.
Request For Free PDF Sample Of This
Research Report At: https://www.reportsanddata.com/sample-enquiry-form/1508
For the purpose of the study,
this Reports and Data has segmented the Global In-Vitro Diagnostics (IVD)
Quality Control Market on the basis of product type, manufacturer type, design,
application, end user and the regional outlook:
Product Type (Revenue, USD
Million; 2016–2026)
- Quality Controls
- Whole Blood-based Controls
- Serum-based Controls
- Plasma-based Controls
- Urine-based Controls
- Other IVD Quality Controls
- Data Management Solutions
- Quality Assurance Services
Manufacturer Type (Revenue,
USD Million; 2016–2026)
- Instrument Manufacturer Controls
- Independent Manufacturer Controls
- Third-party Controls
- Instrument Specific Manufacturer Controls
Application (Revenue, USD
Million; 2016–2026)
- Clinical Chemistry
- Immunochemistry
- Haematology
- Molecular Diagnostics
- Coagulation/Haemostasis
- Microbiology
- Others
End User (Revenue, USD
Million; 2016–2026)
- Hospitals
- Clinical Laboratories
- Home Care
- Others
Regional Outlook: (Revenue,
USD Million; 2016–2026)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Spain
- France
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Middle East and Africa (MEA)
Comments
Post a Comment